Cost-effectiveness of transdiagnostic group cognitive behavioral therapy for emotional disorders in primary care: An analysis of the PsicAP clinical trial.
Journal of Consulting and Clinical Psychology · 2026
DOI: 10.1037/ccp0000990 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Consulting and Clinical Psychology, 2026. Verfasst von Paloma Ruiz-Rodríguez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tres Cantos II Primary Care Centre, Health Service of Madrid. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Cost-Benefit Analysis, Psychotherapy, Group, Cost-Effectiveness Analysis. Gefördert von: MICIU/AEI/10.13039/501100011033, R&D&I Project PID2021-125965OB-I00, MCIN/AEI/10.13039/501100011033.
Abstract (Originalsprache)
Objective/s: Transdiagnostic cognitive behavioral therapy has proven to be an effective treatment for emotional disorders. However, the cost-effectiveness of group Transdiagnostic cognitive behavioral therapy remains unknown. Given the growing demand for psychological care in primary care in the context of limited resources, an economic evaluation of transdiagnostic group cognitive behavioral therapy (TD-GCBT) would provide valuable data for treatment decision making. AIMS: To conduct an economic evaluation of the PsicAP treatment protocol. METHOD: The PsicAP-Costs was a multicenter, randomized controlled trial of 429 patients with a suspected diagnosis of anxiety, depression, and/or somatoform disorders. Participants were randomized to treatment as usual (TAU [control group] or TD-GCBT plus TAU [experimental group]). Treatment consisted of seven sessions of TD-GCBT delivered over a 12-14 week period. RESULTS: The primary efficacy outcomes were significantly better in the TD-GCBT + TAU group, with small to large effect sizes for the reduction of depression, anxiety, and somatization symptoms. The economic evaluation yielded a mean incremental effectiveness of .06 quality-adjusted life years with a mean incremental cost of 263€. This resulted in an incremental cost-effectiveness ratio of 4,759€ per quality-adjusted life year. CONCLUSIONS: The integration of TD-GCBT into TAU represents a cost-effective therapeutic approach. The incremental cost-effectiveness ratio of 4,759€ per quality-adjusted life years is well below the willingness-to-pay threshold accepted in Spain, which ranges from 20,000€ to 25,000€. At this threshold, the probability that the intervention is cost-effective is high, ranging from 86% to 89%. Therefore, the implementation of TD-GCBT in PC may represent a cost-effective option for improving the quality of care for emotional disorders. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Tres Cantos II Primary Care Centre, Health Service of Madrid.
- Department of Personality, Assessment and Psychological Treatments, Faculty of Psychology, University of Valencia.
- Department of Psychology, Universidad Siglo 21.
- Department of Psychology, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid.
- Department of Psychology, International University of La Rioja.
- Faculty of Psychology, University of Cordoba.
ORCID-Profile: Gabriel Esteller-Collado, Antonio Cano-Vindel
Förderung
- MICIU/AEI/10.13039/501100011033
- R&D&I Project PID2021-125965OB-I00
- MCIN/AEI/10.13039/501100011033
Zitieren
APA
Ruiz-Rodríguez, P., Muñoz-Navarro, R., Esteller-Collado, G., Moretti, L., Carpallo-González, M., Prieto-Vila, M., González-Blanch, C., Moriana, J. A., Medrano, L. A., & Cano-Vindel, A. (2026). Cost-effectiveness of transdiagnostic group cognitive behavioral therapy for emotional disorders in primary care: An analysis of the PsicAP clinical trial. Journal of Consulting and Clinical Psychology. https://doi.org/10.1037/ccp0000990
Vancouver
Ruiz-Rodríguez P, Muñoz-Navarro R, Esteller-Collado G, Moretti L, Carpallo-González M, Prieto-Vila M, et al. Cost-effectiveness of transdiagnostic group cognitive behavioral therapy for emotional disorders in primary care: An analysis of the PsicAP clinical trial. Journal of Consulting and Clinical Psychology. 2026. doi:10.1037/ccp0000990
BibTeX
@article{RuizRodrguez2026,
author = {Ruiz-Rodríguez, Paloma and Muñoz-Navarro, Roger and Esteller-Collado, Gabriel and Moretti, Luciana and Carpallo-González, María and Prieto-Vila, Maider and González-Blanch, César and Moriana, Juan Antonio and Medrano, Leonardo Adrián and Cano-Vindel, Antonio},
title = {Cost-effectiveness of transdiagnostic group cognitive behavioral therapy for emotional disorders in primary care: An analysis of the PsicAP clinical trial},
journal = {Journal of Consulting and Clinical Psychology},
year = {2026},
doi = {10.1037/ccp0000990}
}
EUVIMED